Adage Capital Partners, a Boston hedge fund founded by Robert Atchinson, filed a new 13G disclosing ownership of 8,461,868 shares of AMLN as of July 20th. This gives Adage a 5.2% stake in the company and is an increase of 8,450,000 shares over what they reported on their March 31st 13F.
From Yahoo! Finance, Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases.
|Reported via||Date||Name||Ticker||Shares||% of Portfolio|
|13F||2004-12-31||Amylin Pharmaceuticals, Inc.||AMLN||150,000||0.03|
|13F||2006-03-31||Amylin Pharmaceuticals, Inc.||AMLN||150,000||0.06|
|13F||2007-12-31||Amylin Pharmaceuticals, Inc.||AMLN||400,000||0.08|
|13F||2008-12-31||Amylin Pharmaceuticals, Inc.||AMLN||300,000||0.03|
|13F||2010-03-31||Amylin Pharmaceuticals, Inc.||AMLN||500,000||0.05|
|13F||2010-06-30||Amylin Pharmaceuticals, Inc.||AMLN||1,400,000||0.12|
|13F||2010-09-30||Amylin Pharmaceuticals, Inc.||AMLN||850,000||0.08|
|13F||2012-03-31||Amylin Pharmaceuticals, Inc.||AMLN||11,868||0.00|
|SC 13G||2012-07-20||Amylin Pharmaceuticals, Inc.||AMLN||8,461,868||N/A|